Rilonacept 80 mg + Rilonacept 160 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intercritical Gout
Conditions
Intercritical Gout
Trial Timeline
Feb 1, 2009 → Jun 1, 2010
NCT ID
NCT00829829About Rilonacept 80 mg + Rilonacept 160 mg
Rilonacept 80 mg + Rilonacept 160 mg is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Intercritical Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT00829829. Target conditions include Intercritical Gout.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00829829 | Phase 3 | Completed |
Competing Products
1 competing product in Intercritical Gout
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |